Wells Fargo’s Plus Therapeutics PSTV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9 Hold
2
﹤0.01% 6958
2025
Q4
$27 Hold
2
﹤0.01% 6665
2025
Q3
$36 Sell
2
-12
-86% -$147 ﹤0.01% 6561
2025
Q2
$124 Buy
+14
New +$183 ﹤0.01% 6465
2024
Q2
Sell
-1
Closed -$63 7340
2024
Q1
$63 Hold
1
﹤0.01% 6771
2023
Q4
$61 Hold
1
﹤0.01% 6890
2023
Q3
$28 Hold
1
﹤0.01% 7095
2023
Q2
$36 Hold
1
﹤0.01% 7139
2023
Q1
$68 Hold
1
﹤0.01% 7026
2022
Q4
$73 Buy
+1
New +$159 ﹤0.01% 6883
2022
Q3
Hold
0
7203
2022
Q2
Hold
0
7328
2022
Q1
Hold
0
7644
2021
Q4
Hold
0
7674
2021
Q3
Hold
0
7384
2021
Q2
Hold
0
7311
2021
Q1
Hold
0
7259
2020
Q4
Hold
0
6889
2020
Q3
Hold
0
6759
2020
Q2
Hold
0
6693
2020
Q1
Sell
-3
Closed -$2.31K 6659
2019
Q4
$2K Buy
+3
New +$2.75K ﹤0.01% 6180
2019
Q3
Hold
0
6626
2019
Q2
Hold
0
6557
2019
Q1
Hold
0
6366
2018
Q4
Hold
0
6566
2018
Q3
Hold
0
6531
2018
Q2
Hold
0
6511
2018
Q1
Hold
0
6524
2017
Q4
Hold
0
6483
2017
Q3
Hold
0
6432
2017
Q2
Hold
0
6129
2017
Q1
Hold
0
6231
2016
Q4
Hold
0
6171
2016
Q3
Hold
0
6114
2016
Q2
Hold
0
6018
2016
Q1
Hold
0
6039
2015
Q4
Hold
0
6017
2015
Q3
Hold
0
5893
2015
Q2
Hold
0
5661
2015
Q1
Hold
0
5387
2014
Q4
Hold
0
5632
2014
Q3
Hold
0
5509
2014
Q2
Hold
0
4987
2014
Q1
Hold
0
5021
2013
Q4
Hold
0
5091
2013
Q3
Hold
0
4410
2013
Q2
Hold
0
4461

Other funds holding PSTV

Wells Fargo's PSTV Position: Q1 2026 in Review

Wells Fargo held its Plus Therapeutics (PSTV) position steady in Q1 2026 at 2 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #6958.

Wells Fargo first reported a position in PSTV in Q4 2019 and has held it in 11 quarters since. The position peaked at $2K in Q4 2019. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Wells Fargo held 2 shares of Plus Therapeutics worth $9 as of Q1 2026.
  • Wells Fargo left its Plus Therapeutics share count unchanged in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6958 holding.
  • Wells Fargo first reported a position in Plus Therapeutics in Q4 2019 and has held it in 11 quarters since.
  • Wells Fargo's Plus Therapeutics position peaked at $2K in Q4 2019.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.